Preliminary Scientific Program - ICTHIC April 8-10, 2016
Friday April 8
th2016
9,00 - 11,00 am
Industry sponsored session
11,00 - 11,15 am
Congress Opening: A Falanga, FR Rickles, B Brenner
11,15 - 1,30 pm
Plenary Session 1: Epidemiology of thrombosis in cancer
Chairs: N Key (USA); TBA
- Venous thromboembolism and occult cancer: impact on clinical practice M Carrier (Canada)
- Cancer associated thrombosis: risk factors and outcomes S Eichingher (Austria)
- Update of incidental VTE in cancer H Liebman (USA)
- Thrombosis and anticancer therapies: the contribution of chemotherapy and the specific drugs implicated in CAT
P Mismetti (France)
Oral Communications
2,30 - 4,45 pm
Plenary Session 2: Role of hemostatic pathways in cancer progression
Chairs: TBA
- Microparticles and cancer thrombosis in animal models C Dubois (France)
- Inhibition of platelet function as a target for cancer progression control J Italiano (USA)
- Biological basis of personalised anticoagulation in cancer: oncomir networks as regulators of coagulopathy
J Rak (Canada)
- Heparanase procoagulant activity in cancer progression Y Nadir (Israel)
Oral Communications
5,15 - 7,30 pm
Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer
Chairs: B Brenner (Israel); S Kostantinides (Germany)
- Cancer-associated thrombosis novel biomarker discovery
N Kuderer (USA)
- VTE risk assessment models in cancer I Pabinger (Austria)
- Polymorphisms of clotting factors and cancer risk P Sandset (Sweeden)
- The HYPERCAN prospective study
A Falanga (Italy) Oral Communications
7,30 pm
Plenary Lecture
:4th Simon Karpatkin Memorial Lecture
Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA) Introduction to Lecture
FR Rickles (USA)
Targeting clotting proteins in cancer therapy - progress and challenges W Ruf (USA, Germany)
Saturday April 9
th2016
8,30 - 10,45 am
Plenary Session 4
:Hematological malignancies and hemostatic complications
Chairs: TBA
- Intracranial hemorrhage in cancer patients on anticoagulation J Zwicker (USA)
- Management of cancer-associated disseminated intravascular coagulation
M Levi (The Netherlands)
-New insights into the biology and management of thrombosis in myeloproliferative neoplasms
T Barbui (Italy)
- Update of thrombosis in multiple myeloma FWG Leebeek (The Netherlands)
Oral Communications
11,15 am - 1,30 pm
Plenary Session 5
:Risk factors for thrombosis in cancer
Chairs: I Elalamy (France); GM Liumbruno (Italy)
- Upper extremity deep vein thrombosis: comparison between cancer and non-cancer patients
SM Bleker (The Netherlands)
- Risk of thrombosis and supportive care (transfusion, catheters, growth factors)
TBA
- New findings from global registries of cancer-associated thrombosis AK Kakkar (UK)
- Predictors of recurrent VTE and bleeding on anticoagulation
AA Khorana (USA)
Oral Communications
2,30 - 3,00 pm
Special Session: History of ICTHIC
Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel)
History of ICTHIC - How has the field progressed since our first meeting in 2001?
F Rickles (USA)
3,00 - 5,00 pm
Poster sessions with refreshments
Poster walk discussion sessions with chair4,30 - 6,45 pm
Plenary Session 6: Prophylaxis of thrombosis in cancer patients
Chairs: TBA
Thromboprophylaxis in hospitalized Cancer Patients: a comparison of guidelines
M. Levine (USA)
Long term cardiovascular complications of chemotherapy in patients with cancer
P. W. Kamphuisen (The Netherlands)
DOACs in cancer patients - what is known and what are the active trials G Agnelli (Italy)
Oral Communications
Sunday April 10
th2016
8,30 - 10,45 am Plenary Session 7: Treatment of cancer-associated thrombosis
Chairs: H ten Cate (The Netherlands); G Lyman (USA)
- CAT treatment: guidelines update AYY Lee (Canada)
- Management of recurrent venous thromboembolism in cancer patients W Ageno (Italy)
- The use of vena cava filter in patients with cancer T Wun (USA)
- Management of bleeding complications in cancer patients on DOACs S Schulman (Canada)
Oral Communications
11,15 am - 1,30 pm
Plenary session 8: Open questions in cancer and thrombosis
Chairs: H Buller (Germany)
- Anticoagulant and cancer: Will overall survival increase?
HH Veersteg (The Netherlands)
- Does one size fit all? Who should get LMWH/warfarin/DOACs?
S Noble (UK)
- LMWH in cancer patients with renal impairment - better than warfarin?
R Bauersachs (Germany)
- Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients
J Harenberg (Germany) Oral Communications
1,30 - 1,45 pm Concluding Remarks
